摘要
目的观察辛通畅络法复方肾苏Ⅱ对局灶节段性肾小球硬化(FSGS)大鼠肾间质纤维化(RIF)进程及转化生长因子β_1(TGF-β_1)表达的影响。方法 48只健康雄性SD大鼠采用随机数字表法分为对照组12只和造模组36只。造模组大鼠采用阿霉素注射法诱发FSGS型阿霉素肾病模型,再采用随机数字表法均分为模型组、西药组和中药组,西药组0.33mg/100g灌服洛汀新混悬液,中药组3.5g/100g灌服肾苏Ⅱ,模型组及对照组灌服等量生理盐水,共12周。行HE染色、Masson染色观察各组肾小管-间质病理形态改变情况,测定肾小管间质损伤指数和肾小管-间质纤维化指数,并采用免疫组化SP法检测肾小管间质纤维连结蛋白(FN)和TGF-β_1相对表达水平。结果中药组FSGS大鼠肾间质纤维化进程延缓,肾小管-间质损伤指数(1.51±0.80)低于模型组(2.18±0.38)和西药组(1.79±0.24),肾小管-间质纤维化指数(2.39±0.13)低于模型组(3.11±0.25)和西药组(2.80±0.41),肾间质FN相对表达量(14.19±3.06)低于模型组(21.25±3.31)和西药组(18.51±2.29),TGF-β_1相对表达量(2.64±0.21)低于模型组(6.02±0.12)和西药组(3.79±0.46),差异均有统计学意义(均P<0.05)。结论辛通畅络法复方肾苏Ⅱ可延缓FSGS大鼠肾间质纤维化进程,作用机制可能与抑制TGF-β_1表达有关。
Objective To observe and discuss the effect of the traditional Chinese drug complex prescription ShensuⅡfrom Xintong Changluo therapeutic principle on renal interstitial fibrosis (RIF) and transforming growth factor-β1 (TGF-β1) expresssion in focal segmental glomerulosclerosis (FSGS) model rats. Methods Forty-eight healthy male SD rats were randomly divided into control group (n=12) and modeling group (n=36). Rats of modeling group were injected by doxorubicin hydrochoride for FSGS model. Rats of modeling group were sub-divided into model group, benazepril group and TCM group randomly. In 12 weeks, TCM group was given by intragastric administration of ShensuⅡ (3.5 g/100 g), benazepril group was given by intragastric administration of benazepril suspension (0.33 mg/100 g), control group and model group were given by intragastric administration of same volume of saline. HE /Masson staining was used to observe changes of tubulointerstitial pathomorphology. The degree of injury and fibrosis was measured. The expressions of fibronectin (FN) and TGF- β1 were detected by immunohistochemical SP method. Results The process of renal interstitial fibrosis was slower in FSGS rats of TCM group. Renal interstitial pathological index was 1.51±0.80 in TCM group, which was lower than that of model group(2.18±0.38) and benazepril group (1.79±0.24). The index of renal interstitial fibrosis was 2.39±0.13 in TCM group, which was lower than that of model group (3.11±0.25) and benazepril group (2.80±0.41). The relative expression of FN in renal interstitial was 14.19±3.06 in TCM group, which was lower than that of model group (21.25±3.31) and benazepril group (18.51±2.29). The relative expression of TGF-β1 in renal interstitial was 2.64±0.21 in TCM group, which was lower than that of model group (6.02±0.12) and benazepril group (3.79±0.46). All the differences were statistically significant (P<0.05).Conclusion Xintong Changluo complex prescription ShensuⅡcan reduce the process of renal interstitial fibrosis in FSGS model rats, which may be related with the inhibiting expression of TGF-β1.
作者
窦一田
李翀
马鸿杰
张涛
DOU Yi-tian;LI Chong;MA Hong-jie;ZHANG Tao(The First Affiliated Hospital of Tianjin University of TCM, Tianjin 300381, China)
出处
《天津医药》
CAS
2017年第3期239-244,共6页
Tianjin Medical Journal
基金
国家自然科学基金青年科学基金项目(81403333)
天津市应用基础与前沿技术研究计划项目(14JCQNJC11400)
天津市高等学校科技发展基金计划项目(20130210)
天津市卫生和计划生育委员会中医中西医结合科研课题项目(2015102)
关键词
肾小球硬化症
局灶节段性
转化生长因子Β1
肾间质纤维化
辛通畅络法
肾苏Ⅱ
glomerulosclerosis, focal segmental
transforming growth factor beta 1
renal interstitial fibrosis
Xintong Changluo therapeutic principle
ShensuⅡ
